托法西提尼布和巴里西提尼布在2型糖尿病患者的类风湿性关节炎
Cristina Martinez-Molina1,2, Cesar Diaz-Torne2,3, Hye S Park2,3
1Department of Pharmacy, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Medicina (Kaunas, Lithuania)
|March 28, 2024
概括
在患有2型糖尿病 (T2DM) 的类风湿性关节炎患者中,巴里西提尼布治疗改善了血糖控制,降低了HbA1c水平. 托法西提尼布和巴里西提尼布也有效地控制了类风湿性关节炎疾病的活动.
科学领域:
- 类风湿病学 类风湿病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于JAK抑制剂对类型2糖尿病 (T2DM) 在类风湿性关节炎 (RA) 患者的影响的临床证据有限.
- 一项先前的研究表明,巴里西提尼布可以在糖尿病患者中保持β细胞功能.
研究的目的:
- 评估托法西提尼布和巴里西提尼布对T2DM RA患者血糖控制 (HbA1c) 和疾病活性的影响.
- 评估JAK抑制剂治疗期间体重指数 (BMI) 的变化.
主要方法:
- 这是一项对13名患有T2DM的RA患者进行的观察性,回顾性,单中心研究,这些患者正在服用口服抗糖尿病药物 (OADs).
- 患者接受托法西提尼布或巴里西提尼布治疗6个月.
- 主要结局:HbA1c变化;次要结局:BMI和RA疾病活动.
主要成果:
- 在6个月后,巴里西替尼显著降低了HbA1c (p=0.035),57.1%的人达到<7%的HbA1c.
- 在28.6%的患者中,巴里西提尼布治疗导致BMI增加 (p=0.022) 和OAD剂量减少.
- 两种JAK抑制剂都实现了RA缓解或低疾病活性,而无需改变RA治疗方法.
结论:
- 巴里西丁尼可能会增强T2DM患者的胰岛素敏感性和葡萄糖吸收,有助于糖尿病管理.
- 在这种患者群体中,JAK抑制剂有效控制RA疾病活动.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138